Related Experiment Video
Updated: Oct 7, 2025
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
Low-dose ranibizumab administration in retinopathy of prematurity
Levent Tök1, Lütfi Seyrek2,3, Özlem Yalçın Tök2
1Department of Ophthalmology, Faculty of Medicine, Süleyman Demirel University Hospital, 32260, Çünür, Isparta, Turkey. dr.leventtok@yahoo.com.tr.
Insights
Low-dose intravitreal ranibizumab effectively treats aggressive retinopathy of prematurity (A-ROP), leading to regression in most cases. This treatment offers a wide visual field, even with rescue therapy.
Area of Science:
- Ophthalmology
- Neonatology
- Pharmacology
Background:
- Aggressive retinopathy of prematurity (A-ROP) is a severe condition requiring effective treatment.
- Intravitreal ranibizumab is an emerging therapy for ROP.
Purpose of the Study:
- To evaluate the efficacy of low-dose intravitreal ranibizumab for A-ROP.
Main Methods:
- Retrospective analysis of 124 eyes from 62 patients diagnosed with A-ROP.
- Administration of low-dose intravitreal ranibizumab with regular follow-up.
Main Results:
- ROP regression occurred within one week post-injection in all eyes.
- 58 eyes achieved regression with a single dose; 38 required a second.
- No ocular or systemic side effects were reported.
Conclusions:
- Low-dose intravitreal ranibizumab is an effective treatment for A-ROP when administered timely.
- This therapy facilitates a wide visual field, even when rescue treatments are necessary.
Purpose:
To evaluate the efficiency of low-dose intravitreal ranibizumab therapy in the treatment of aggressive retinopathy of prematurity (A-ROP).
Methods:
A total of 124 eyes of 62 patients who underwent intravitreal ranibizumab after an A-ROP diagnosis between January 2015 and January 2021 were evaluated retrospectively. After receiving family-approved informed consent, low-dose intravitreal ranibizumab was administered, and regular follow-ups were performed.
Results:
Patients included in the study had a mean birth week of 26.6 (23-33 weeks), a mean birth weight of 905 (450-1970) grams, and an average injection postnatal time of 9.1 (4-19) weeks. The mean follow-up period was 63 (24-250) weeks. In all eyes, ROP regressed in the first week after injection, and no asymmetrical response was observed in the eyes of any baby. A total of 58 eyes recovered with a single dose of intravitreal injection therapy, and peripheral retinal vascularization was completed. A second injection was required in 38 eyes. Rescue treatment was applied in addition to intravitreal ranibizumab treatment in 22 eyes of 11 babies. None of the patients had any ocular or systemic side effects.
Conclusion:
Low-dose intravitreal ranibizumab injection with close follow-up and appropriate timing is an effective treatment modality in A-ROP. Even among patients undergoing rescue laser treatment, the treatment can be completed with a wide visual field.
More Related Videos
07:49Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
Published on: September 17, 2014
11:03Subretinal Transplantation of Human Embryonic Stem Cell Derived-retinal Pigment Epithelial Cells into a Large-eyed Model of Geographic Atrophy
Published on: January 22, 2018
